Current Issue

View Larger Image

Past Issues Free Subscriptions
Sponsored
Keywords



Search Results - Biogen Idec
 More »

  • Creative Acquisition in Biotech, Take Two
    companies in 2012 were, in descending order: Amgen, Gilead Sciences, Biogen Idec, Celgene, Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Alexion ...
    8-1-2013
  • What the Top 15 Biopharma CEOs Are Making
    ... % Change: 60.6% Position on 2012 List: Not ranked #12. George A. Scangos Company: Biogen Idec Full title: CEO 2012 Compensation: $13,451,802 2011 Compensation: $11,331,441 % ...
    7-31-2013
  • Samsung Biologics, BMS in Manufacturing Partnership
    Although a relatively young company, this isn't Samsung Biologics' first major deal: In December 2011, the firm established a joint venture with Biogen Idec to develop and market ...
    7-29-2013
  • Perrigo Buying Elan for $8.6B
    Tysabri, which Elan co-developed with Biogen Idec, racked up $1.6 billion in sales last year, up nearly 8% from $1.5 billion in 2011, with Biogen Idec receiving $1.1 billion of ...
    7-29-2013
  • Adimab Licenses Antibody Platform to GSK, Biogen Idec
    today it signed an antibody transfer and license with GlaxoSmithKline, while extending along similar lines an existing two-year-old antibody-based collaboration with Biogen Idec. ...
    7-26-2013
  • Novo Nordisk Tops GEN List of Top 25 Biotech Companies
    market cap, Gilead Sciences (NASDAQ:GILD) at $78.4 billion, Celgene (NASDAQ:CELG) coming in at $52.6 billion, and Biogen Idec (NASDAQ:BIIB), having a market cap of $47.2 billion. ...
    7-25-2013
  • Biogen Idec, University of Edinburgh Team Up for Neurodegenerative...
    Biogen Idec and the University of Edinburgh have agreed to a three-year collaboration in which they plan to study multiple sclerosis (MS) and motor neuron disease, then identify ...
    7-19-2013
  • Top 25 Biotech Companies of 2013
    ... shares * price $45.06 on 3/30) 4,9 % Change: -14.1% Position on 2012 List: #5 #5. Biogen Idec 2013 Market Cap: $47.157 billion (4/18: 237,374,815 shares * price $198.66) 2012 ...
    7-15-2013
  • People in the News
    Spyros Artavanis-Tsakonas, Ph.D. Spyros Artavanis-Tsakonas, Ph.D. , is now CSO at Biogen Idec. He is currently a professor of cell biology at Harvard Medical School, where he was ...
    7-10-2013
  • Biogen Idec, Sobi Cite Promising Phase III Results for Hemophilia...
    Biogen Idec and Sobi today presented data from the Phase III A-LONG trial showing that their long-lasting recombinant factor VIII candidate Eloctate for hemophilia A could ...
    7-5-2013
  • Biogen Idec, Myelin Repair Foundation Eye New Mouse Model Against...
    Biogen Idec won a nonexclusive sublicense from the Myelin Repair Foundation (MRF) for the use of its technologies in developing a new mouse model for multiple sclerosis (MS) and ...
    7-1-2013
  • Adaptive, Biogen Idec Ink Immunological Biomarkers Agreement
    Adaptive Biotechnologies and Biogen Idec are together searching for immunological biomarkers for difficult-to-treat autoimmune diseases, the firms said. Financial terms were not ...
    6-27-2013
  • Top 20 Corporate Venture Funds
    Also not included in the list is the former Biogen Idec New Venture Fund, which the company shut down in 2011, along with a startup incubator, in a shift of resources to internal ...
    6-14-2013
  • Strategies to Optimize Cell Culture
    ... Lam Raga Anggara Markley, Ph.D., scientist, Biogen Idec, discusses an improved high-throughput assay for SA content (high-throughput total sialic acid assay (HT-TSA)) that was ...
    6-1-2013
  • Novo Nordisk Reports Promising Phase III Results for Hemophilia...
    ... to bring a recombinant Factor IX to market is Biogen Idec and Swedish Orphan Biovitrum, which last year also published promising Phase III clinical trial results for their product. ...
    5-17-2013

  • Journal Articles

  • Testicular Uptake and Radiation Dose in Patients Receiving Zevalin...
    Sui Shen, Ruby Meredith, Jun Duan, Andres Forero, Hazel Breitz, M.B. Khazaeli, Ivan Brezovich, Albert LoBuglio
    Cancer Biotherapy and Radiopharmaceuticals
    a Zevalin(tm) (Biogen Idec, Cambridge, MA) regimen and 6 male colorectal cancer patients who received a Pretarget(tm) (Neo Rx, Seattle, WA) CC49Fusion protein were evaluated. ...
  • Effect of Antilymphoma Antibody, 131 I-Lym-1, on Peripheral Blood...
    Orazio Schillaci, Gerald L. DeNardo, Sally J. DeNardo, Desiree S. Goldstein, Linda A. Kroger, Robert T. O'Donnell, Kathleen R. Lamborn
    Cancer Biotherapy and Radiopharmaceuticals
    Cancer Biotherapy and Radiopharmaceuticals ABSTRACT Anti-CD20 monoclonal antibodies (mAbs), unlabeled rituximab (Rituxan®, Biogen Idec Inc., Cambridge, MA; and Genentech Inc., ...
  • Transfer of Interferon β-1a into Human Breastmilk
    Thomas W. Hale, Afzal A. Siddiqui, Teresa E. Baker
    Breastfeeding Medicine
    and provides an estimate of infant exposure to this antiviral in six women chronically receiving intramuscular interferon ß-1a (Avonex®, Biogen Idec, Research Triangle Park, NC). ...

GEN Webinars

View »

GEN Web Briefs

View »

GEN Poll

More » Poll Results » Archive »

Top Paid Women in Biopharma

Do you think the women on our list of the 20 top paid women executives in biopharma are underpaid?

Suggest a Poll